Japan’s Itochu Biologic Subsidiary To Launch First Drug In Taiwan
This article was originally published in PharmAsia News
Executive Summary
Japanese major trading house Itochu's bioventure subsidiary, Tokyo-based Solasia Pharma K.K., plans to launch its first drug to the Taiwanese market within the year. The drug, Sancuso (transdermal granisetron) patch is for chemotherapy-induced nausea and vomiting. Solasia also is preparing to launch the drug in China and other Asian markets. Compared to current oral therapy, the Sancuso patch allows patients with swallowing difficulties to use it. The company aims for ¥8 billion in annual sales by 2015. (Click here for more - Japanese language
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.